Back to Search
Start Over
Thyroid carcinoma, version 2.2014.
- Source :
-
Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2014 Dec; Vol. 12 (12), pp. 1671-80; quiz 1680. - Publication Year :
- 2014
-
Abstract
- These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or cabozantinib may be recommended for select patients with metastatic medullary thyroid carcinoma. Other kinase inhibitors may be considered for select patients with either type of thyroid carcinoma. A new section on "Principles of Kinase Inhibitor Therapy in Advanced Thyroid Cancer" was added to the NCCN Guidelines to assist with using these novel targeted agents.<br /> (Copyright © 2014 by the National Comprehensive Cancer Network.)
- Subjects :
- Adenocarcinoma pathology
Anilides therapeutic use
Carcinoma, Neuroendocrine
Guidelines as Topic
Humans
Neoplasm Metastasis
Niacinamide analogs & derivatives
Niacinamide therapeutic use
Phenylurea Compounds therapeutic use
Pyridines therapeutic use
Sorafenib
Thyroid Neoplasms pathology
Adenocarcinoma drug therapy
Protein Kinase Inhibitors therapeutic use
Thyroid Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1540-1413
- Volume :
- 12
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of the National Comprehensive Cancer Network : JNCCN
- Publication Type :
- Academic Journal
- Accession number :
- 25505208
- Full Text :
- https://doi.org/10.6004/jnccn.2014.0169